Table 4. Stimulation parameters, medication quantification scales and analgesic effects per patient.
| Diagnosis | Groupa | Pain relief, %, after 3 years of MCS |
Level of pain controlb | Intensity, Vc | Frequency, Hzc | Pulse width, μsc | MQSpre | MQSpost | Changes in MQSd | QLI pre | QLI post | Changes in QLIe | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | PSP | A | 54 | 2 | 2 | 50 | 90 | 16.5 | 4.2 | Diminished | N/A | N/A | N/A |
| 2 | PSP | A | 56 | 2 | 1.5 | 50 | 80 | 5.4 | 5.4 | No change | N/A | N/A | N/A |
| 3 | PSP | A | 60 | 2 | 2.5 | 50 | 60 | 15.3 | 13.2 | Diminished | 9 | 7 | Diminished |
| 4 | PSP | A | 70 | 1 | 2.5 | 60 | 60 | 6.3 | 4.2 | Diminished | 14 | 2 | Diminished |
| 5 | TN1 | A | 100 | 1 | 3 | 50 | 60 | 8.2 | 0 | Diminished | 7 | 2 | Diminished |
| 6 | TN1 | A | 67 | 2 | 4.5 | 40 | 90 | 0 | 0 | No change | 14 | 4 | Diminished |
| 7 | TN2 | A | 60 | 2 | 4.5 | 50 | 120 | 6.3 | 4.8 | Diminished | 8 | 4 | Diminished |
| 8 | PSP | B | 20 | 3 | 2.5 | 50 | 90 | 26.1 | 4.2 | Diminished | 7 | 1 | Diminished |
| 9 | PSP | B | 38 | 3 | 3 | 50 | 60 | 14.1 | 4.2 | Diminished | 11 | 10 | Diminished |
| 10 | PSP | B | 20 | 3 | 2.5 | 50 | 60 | 0 | 5.4 | Increased | 16 | 16 | No change |
| 11 | PIFP | B | 20 | 3 | 4 | 50 | 60 | 11.5 | 8.4 | Diminished | 16 | 12 | Diminished |
| 12 | PIFP | B | 25 | 3 | 5 | 50 | 90 | 6.3 | 6.9 | Increased | 13 | 13 | No change |
| 13 | CPSP | B | 25 | 3 | 3 | 50 | 60 | 6.4 | 7.8 | Increased | 16 | 8 | Diminished |
| 14 | TNP | B | 0 | 3 | 3 | 40 | 60 | 6.8 | 10.7 | Increased | 12 | 10 | Diminished |
| 15 | TNP | B | 10 | 3 | 2 | 40 | 80 | 23.4 | 15.6 | Diminished | 11 | 10 | Diminished |
| 16 | BMS | B | 11 | 3 | 3 | 40 | 90 | 5. | 5.4 | No change | 8 | 8 | No change |
| 17 | PhP | B | 12.5 | 3 | 2.5 | 50 | 60 | 6.3 | 12 | Increased | N/A | N/A | N/A |
| 18 | AvP | B | 30 | 3 | 3 | 50 | 60 | 24.6 | 14.2 | Diminished | 17 | 8 | Diminished |
a Group A, responding patients; group B, non-responding patients
b Level 1, 70–100%; level 2, 40–69%; level 3, 0–39%.
c Stimulation parameters that were reported at the last follow-up.
d Dimished, MQS after MCS<MQS before MCS (negative rank); Increased, MQS after MCS>MQS before MCS (positive rank); No change, MQS after MCS equal to MQS before MCS (tie).
e Dimished, QLI after MCS<QLI before MCS (negative rank); Increased, QLI after MCS>QLI before MCS (positive rank); No change, QLI after MCS equal to QLI before MCS (tie).
AvP, avulsion pain; BMS, burning mouth syndrome; BPAP, brachial plexus avulsion pain; CPSP: Chronic post surgical pain; Hz, Hertz; μs, microseconds; MCS, motor cortex stimulation; MQS, medication quantification scale; MQSpost, medication quantification scale following MCS; MQSpre, medication quantification scale before MCS; N/A, Not available; PIFP, persistent idiopathic facial pain; PSP, post-stroke pain; QoL-index pre, Quality of life index before MCS; QoL-index post, Quality of life index following MCS; TN1, trigeminal neuralgia type 1 (>50% episodic); TN1, trigeminal neuralgia type 1 (>50% constant); TNP, trigeminal neuropathic pain